Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

被引:89
作者
Leung, AT
Malmstrom, K
Gallacher, AE
Sarembock, B
Poor, G
Beaulieu, A
Castro, R
Sanchez, M
DeTora, LM
Ng, J
机构
[1] Merck Res Labs, Rahway, NJ 07065 USA
[2] Hosp Britanico, Buenos Aires, DF, Argentina
[3] Christiaan Barnard Mem Hosp, Cape Town, South Africa
[4] Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary
[5] Lab Rech Arthrite, Ste Foy, PQ, Canada
[6] Colegio Med Costa Rica, San Juan, Costa Rica
关键词
etoricoxib; naproxen; non-steroidal anti-inflammatory drugs; cyclo-oxygenase; osteoarthritis;
D O I
10.1185/030079902125000282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:To evaluate the efficacy of 12 weeks of treatment with etoricoxib, a selective COX-2 inhibitor, in patients with osteoarthritis (OA) of the knee or hip. Methods: In the 12-week placebo- and active comparator-controlled period of a randomized, double-blind study, eligible patients were treated with etoricoxib 60 mg once daily (n = 224), naproxen 500 mg twice daily (n = 221), or placebo (n = 56). Western Ontario McMaster's Osteoarthritis Index (WOMAC) pain and physical function subscales and patient's global assessment of disease status were primary end points. Key secondary and other end points were patient's and investigator's global assessment of response to therapy, WOMAC stiffness subscale, investigator's global assessment of disease status, rescue paracetamol use, proportion of patients discontinuing due to lack of efficacy, and study joint tenderness. Results: Etoricoxib 60 mg demonstrated efficacy significantly superior to placebo (p less than or equal to 0.005) and comparable to naproxen 500 mg twice daily as assessed by the primary efficacy end points. Secondary and other end points confirmed these results. Treatment effects were evident by day 2, maximal by week 2, and sustained over the entire 12 weeks. Etoricoxib was well tolerated for 12 weeks. Conclusions: Etoricoxib showed rapid and durable treatment effects in patients with OA of the knee or hip. Etoricoxib was generally well tolerated.
引用
收藏
页码:49 / 58
页数:10
相关论文
共 30 条
[1]   Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society - Results from a workshop [J].
Altman, R ;
Brandt, K ;
Hochberg, M ;
MOskowitz, R ;
Bellamy, N ;
Bloch, DA ;
Buckwalter, J ;
Dougados, M ;
Ehrlich, G ;
Lequesne, M ;
Lohmander, S ;
Murphy, WA ;
RosarioJansen, T ;
Schwartz, B ;
Trippel, S .
OSTEOARTHRITIS AND CARTILAGE, 1996, 4 (04) :217-243
[2]  
[Anonymous], 1982, DRUG INF J
[3]  
BELLAMY N, 1988, J RHEUMATOL, V15, P1833
[4]  
BOLOGNESE J, 1998, ARTHRITIS RHEUM, V41, pS144
[5]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[6]  
Botting J, 1996, DRUG NEWS PERSPECT, V9, P123
[7]   Renal effects of COX-2-selective inhibitors [J].
Brater, DC ;
Harris, C ;
Redfern, JS ;
Gertz, BJ .
AMERICAN JOURNAL OF NEPHROLOGY, 2001, 21 (01) :1-15
[8]  
Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO
[9]  
2-0
[10]  
Catella-Lawson Francesca, 2001, American Journal of Medicine, V110, p28S